Monthey, Switzerland, 27/02/2024 – ExcellGene, a renowned Swiss biologics CDMO specializing in complex protein manufacturing services, using standard CHO and HEK293 expression systems and Capricorn Scientific, a leading German manufacturer of high-quality cell culture products, have joined forces in a strategic partnership to elevate the field of biopharmaceutical production.

Two Companies, One Vision

ExcellGene boasts over two decades of experience in developing CHO and HEK cell lines, suitable for GMP manufacturing, along with crafting manufacturing processes, with a deep understanding of process sciences, including understanding bioreactor environment for mammalian suspension cultures and bioprocess development. The company is known for its unparalleled scientific expertise offering high quality results, and cost-effective solutions on time and impressive track record in developing cutting-edge technologies with impact in the biotech industry.

On the other hand, Capricorn Scientific brings to the table its expertise in manufacturing media under GMP conditions, ensuring the highest quality and performance of cell culture ingredients for biopharmaceutical production.

Synergies Unleashed with CHOventure

By combining the unparalleled expertise of ExcellGene and the manufacturing excellence of Capricorn Scientific, the partnership has birthed a groundbreaking solution: CHOventure, the new CHO medium family designed to revolutionize biopharmaceutical production.

CHOventure represents the culmination of applied science and manufacturing precision, developed by ExcellGene and manufactured at the highest standards by Capricorn Scientific. This innovative CHO medium family is meticulously crafted to meet the demands of modern biopharmaceutical facilities and regulations, bringing state of the art  technology directly into your production facility.

A Message from the CEO

Dr. Maria Wurm, CEO of ExcellGene, expressed her passion and satisfaction about the partnership, stating, “Our collaboration with Capricorn Scientific marks a milestone in our scientific journey and completes our service offering. Together, we embark on a mission to offer to our clients a CHO medium family, with related feeds particularly suitable to our CHOExpress®-based manufacturing platform but also to other CHO-based production systems, from GS, to MTX gene amplification, to transposon-mediated gene expression, covering production from pool to clonal populations. Furthermore, the design used during the development of this CHO medium family, created an opportunity for boosting high productivity in CHO-based processes in general, but also and importantly during biosimilar development. In fact it provides the flexibility to fine-tune the formulation to achieve specific Critical Quality Attributes (CQAs) during biosimilar process development phases, when associated with the right analytical setting. This partnership represents a convergence of expertise and innovation, and we are thrilled to lead the way in advancing biopharmaceutical production.”

For further information, please contact:
Benjamin Moritz
Business Development Manager
+41 24 471 96 60